Rezolute, Inc.: Business Overview, Financials & Competitive Analysis
Rezolute, Inc. scores 3/10 on the AskCyborg Cyborg Score (Challenged). High-risk biotech with failed lead indication pivoting to alternative pathways; significant downside from recent clinical setback. The Phase 3 sunRIZE study did not meet its primary or key secondary endpoints. The company faces significant clinical and regulatory headwinds following trial failure, though it retains cash reserves and continues development in.
What is Rezolute, Inc.'s industry? Rezolute, Inc. (rezolutebio.com) operates in Biopharmaceutical - Rare Disease/Metabolic Disorders. AskCyborg classifies Rezolute, Inc. under Biopharmaceutical - Rare Disease/Metabolic Disorders in its company registry.
Rezolute is a late-stage rare disease company focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously admi...
Cyborg Score thesis
High-risk biotech with failed lead indication pivoting to alternative pathways; significant downside from recent clinical...
Read the full analyst-debate transcript →Get the Latest Rezolute, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeRezolute, Inc. Overview
Pro stress-test →Rezolute is a late-stage rare disease company focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody in Phase 3 clinical trial for treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for hypoglycemia and tumor hyperinsulinism.
Strategic Profile
Pro stress-test →The Phase 3 sunRIZE study did not meet its primary or key secondary endpoints, though some biomarker and CGM signals were observed. The company is pursuing FDA regulatory pathway discussions and has an ongoing Phase 3 tumor hyperinsulinism (upLIFT) study with topline data expected in H2 2026, positioning itself in the ultra-rare metabolic disease treatment space.
Competitive Landscape
Pro stress-test →Rezolute competes in the ultra-rare metabolic disease space with limited direct competitors given the niche nature of congenital and tumor hyperinsulinism. The company is a clinical-stage developer without approved medicines, positioning itself against potential future therapies from larger pharma and biotech firms entering this space.
Industry Context
Rezolute, Inc. operates in Biopharmaceutical - Rare Disease/Metabolic Disorders.
Key facts
Founded: 2010 · Headquarters: Redwood City, CA · Employees: 64 · Revenue: $0.00B · Market cap: $178.0M